npj Precision Oncology (Nov 2022)
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
Abstract
Abstract The combination of KRAS G12C inhibitors with EGFR inhibitors has reproducibly been shown to be beneficial. Here, we identify another benefit of this combination: it effectively inhibits both wild-type and mutant RAS. We believe that targeting both mutant and wild-type RAS helps explain why this combination of inhibitors is effective.